AbbVie Completes Acquisition Of Cerevel; Reaffirms Full-year Adj. EPS Guidance Range

AbbVie (ABBV) has completed its acquisition of Cerevel Therapeutics. Cerevel is now part of AbbVie. The acquisition is expected to be accretive to adjusted earnings per share beginning in 2030.